AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$TEM

Polovin Andrew sold $1.5M of TEM

Polovin Andrew (EVP, Chief Legal Officer) sold 30,075 shares of Tempus AI, Inc. (TEM) at an average of $51.29 ($49.61–$56.00, $1.54M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polovin Andrew
Published Aug 21, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 1:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings but is unlikely to trigger a sizable market reaction.

02

Market read

A modest insider sale that may cause slight short‑term price pressure but is not a major catalyst.

03

What to watch

Potential upcoming legal matters or personal tax planning that prompted the sale, not necessarily negative sentiment.

Relevance 5/10Novelty 7/10Timing: post‑market filing on 2026‑08‑20

Background

Form 4 filings disclose insider trades and are considered primary sources of new corporate information.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

EVP and Chief Legal Officer sold 30,075 shares for $1.54M via a 10b5‑1 plan, reducing his stake to 138,140 shares.

Expected impact

Potential short‑term downward pressure of 1‑2% if market interprets negatively.

Evidence & confidence

The sale is a primary Form 4 filing, new information, but the amount is not material enough to drive a large move.

Market effects

Sector

Minimal impact on the AI/health‑tech sector; insider activity is routine.

Regional

No significant regional effect.

Global

Limited to investors tracking insider transactions.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain stable.

Key entities

  • Officer
    Polovin Andrew

    EVP and Chief Legal Officer of Tempus AI, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min